Trial Profile

A phase I study of ANS-858

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 07 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ANS 858 (Primary)
Indications Alcoholism; Substance-related disorders
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

07 Apr 2025 New trial record
02 Apr 2025 Arccording to Amygdala Neurosciences media release, the company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and advance ANS-858 into Phase 1 clinical trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com